Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor

被引:16
作者
Burch, Jason D. [1 ]
Belley, Michel [1 ]
Fortin, Rejean [1 ]
Deschenes, Denis [1 ]
Girard, Mario [1 ]
Colucci, John [1 ]
Farand, Julie [1 ]
Therien, Alex G. [1 ]
Mathieu, Marie-Claude [1 ]
Denis, Danielle [1 ]
Vigneault, Erika [1 ]
Levesque, Jean-Francois [1 ]
Gagne, Sebastien [1 ]
Wrona, Mark [1 ]
Xu, Diagen [1 ]
Clark, Patsy [1 ]
Rowland, Steve [1 ]
Han, Yongxin [1 ]
机构
[1] Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada
关键词
D O I
10.1016/j.bmcl.2008.01.103
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new series of EP4 antagonists based on a quinoline acylsulfonamide scaffold have been identified as part of our ongoing efforts to develop treatments for chronic inflammation. These compounds show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. Acceptable pharmacokinetic profiles have also been demonstrated across a series of preclinical species. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2048 / 2054
页数:7
相关论文
共 26 条
[1]   The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs [J].
Abramovitz, M ;
Adam, M ;
Boie, Y ;
Carrière, MC ;
Denis, D ;
Godbout, C ;
Lamontagne, S ;
Rochette, C ;
Sawyer, N ;
Tremblay, NM ;
Belley, M ;
Gallant, M ;
Dufresne, C ;
Gareau, Y ;
Ruel, R ;
Juteau, H ;
Labelle, M ;
Ouimet, N ;
Metters, KM .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1483 (02) :285-293
[2]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[3]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[4]   AH23848 - A THROMBOXANE RECEPTOR BLOCKING DRUG THAT CAN CLARIFY THE PATHOPHYSIOLOGIC ROLE OF THROMBOXANE-A2 [J].
BRITTAIN, RT ;
BOUTAL, L ;
CARTER, MC ;
COLEMAN, RA ;
COLLINGTON, EW ;
GEISOW, SP ;
HALLETT, P ;
HORNBY, EJ ;
HUMPHREY, PPA ;
JACK, D ;
KENNEDY, I ;
LUMLEY, P ;
MCCABE, PJ ;
SKIDMORE, IF ;
THOMAS, M ;
WALLIS, CJ .
CIRCULATION, 1985, 72 (06) :1208-1218
[5]  
Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
[6]   Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence [J].
Chell, SD ;
Witherden, AR ;
Dobson, RR ;
Moorghen, M ;
Herman, AA ;
Qualtrough, D ;
Williams, AC ;
Paraskeva, C .
CANCER RESEARCH, 2006, 66 (06) :3106-3113
[7]   Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human [J].
Cipollone, F ;
Fazia, ML ;
Iezzi, A ;
Cuccurullo, C ;
De Cesare, D ;
Ucchino, S ;
Spigonardo, F ;
Marchetti, A ;
Buttitta, F ;
Paloscia, L ;
Mascellanti, M ;
Cuccurullo, F ;
Mezzetti, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (09) :1925-1931
[8]   Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2. [J].
FitzGerald, GA ;
Patrono, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :433-442
[9]   The development of COX2 inhibitors [J].
Flower, RJ .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (03) :179-191
[10]   COX-2 inhibitors and cardiovascular risk [J].
Funk, Colin D. ;
FitzGerald, Garret A. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) :470-479